Association of loss of heterozygosity and PTEN gene abnormalities with paraclinical, clinical modalities and survival time of glioma patients in Malaysia

Asian Journal of Surgery

Volumn 29, Issue 4, 2006, Pages 274-282

  Abdullah, Jafri Malin ^a,c   Farizan, Ahmad ^a   Asmarina, Ku ^a   Zainuddin, Norafiza ^a   Ghazali, Mazira Mohamad ^a   Jaafar, Hasnan ^a   Isa, Mohd Nizam ^b   Naing, Nyi Nyi ^a  

^a SCHOOL OF MEDICAL SCIENCES   (Malaysia)

^b UNIVERSITI TEKNOLOGI MARA   (Malaysia)

^c SCHOOL OF HEALTH SCIENCES   (Malaysia)

Author keywords

Gliomas; LOH; Malaysian; Prognosis; PTEN mutations; Survival

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ADULT; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CLINICAL ARTICLE; CONFORMATION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GLIOMA; HETEROZYGOSITY LOSS; HUMAN; MALAYSIA; MALE; OUTCOME ASSESSMENT; SURVIVAL TIME; TUMOR VASCULARIZATION;

EID: 33750708233     PISSN: 10159584     EISSN: 02193108     Source Type: Journal    
DOI: 10.1016/S1015-9584(09)60102-0     Document Type: Article

References (28)

1. Kanzawa T, Ito H, Kondo Y, et al. Current and future gene therapy for malignant gliomas. J Biomed Biotechnol 2003;3:25-34.
2. Yusoff AA, Abdullah J, Abdullah MR, et al. Clinicopathological study: association of p53 tumor suppressor gene with paraclinical and clinical modalities of gliomas patients in Malaysia. Acta Neurochir (Wien) 2004;146:595-601.
3. Lam PYP, Breakefield XO. Potential of gene therapy for brain tumors. Hum Mol Genet 2001;10:777-87.
4. Abdullah JM, Zainuddin N, Sulong S, et al. Molecular genetic analysis of phosphatase and tensin homolog and p16 tumor suppressor genes in patients with malignant glioma. Neurosurg Focus 2003;14:Article 6.
5. Stahl JM. Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res 2003;63:12881-90.
6. Lee S, Kim J, Rhee C, et al. Loss of heterozygosity on chromosome 10, 13q 9 (Rb), 17p and p53 gene mutations in human brain gliomas. J Korean Med Sci 1995;10:442-8.
7. Fujisawa H, Reis RM, Nakamura M, et al. Loss of heterozygosity on chromosome 10 is more extensive primary (de novo) than in secondary glioblastoma. Lab Invest 2000;80:65-72.
8. Cheng Y, Ng H, Ding M, et al. Molecular analysis of microdissected de neve glioblastoma and paired astrocytic tumors. J Neuropathol Exp Neurol 1999;58:120-8.
9. Balesaria S, Brock C, Bower M, et al. Loss of chromosome 10 is an independent prognostic factor in high-grade gliomas. Br J Cancer 1998;81:1371-7.
10. Bower M, Brock C, Balesaria S, et al. Allelotype analysis for loss of chromosome 10 in high grade gliomas. European Society for Medical Oncology. (Abstract number: 581)
11. Okumura A, Takenaka K, Nishimura Y, et al. The characterization of human brain tumor using magnetization transfer technique in magnetic resonance imaging. Neurol Res 1999;21:250-4.
12. Lote K, Egeland T, Hoger B, et al. Prognostic significance of CT contrast enhancement within histological subgroups of intracranial glioma. J Neurooncol 1998;40:161-70.
13. Ropper AH. Lateral displacement of the brain and level of consciousness in patients with acute hemispheral mass. N Engl J Med 1986;314:953-8.
14. Yusoff MR, Abdullah J, Isa MN. Brain tumours in rural North East Malaysia. J Islamic Acad Sci 1998;11:121-9.
15. Karnofsky DA, Burchenal JH. In: Macleod CM, ed. Evaluation of Chemotherapy Agents. New York: Columbia University Press, 1949:191-205.
16. Kleihues P, Burger PC, Scheithauer BW. Histological Typing of Tumours of the Central Nervous System. Berlin: Springer-Verlag, 1993.
17. Scarisbrick JJ, Woolford AJ, Russell-Jones R, et al. Loss of heterozygosity on 10q and microsatellite instability in advanced stages of primary cutaneous T-cell lymphoma and possible association with homozygous deletion of PTEN. Blood 2000;95:2937-42.
18. Sakai A, Thieblemont C, Wellmann A, et al. PTEN gene alterations in lymphoid neoplasm. Blood 1998;92:3410-5.
19. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Science 1997;275:1943-7.
20. Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumor suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997;15:356-62.
21. Watling CJ, van Meyel DJ, Ramsay DA, et al. Loss of heterozygosity analysis of chromosome 9, 10, and 17 in gliomas in families. Can J Neurol Sci 1995;22:17-21.
22. Bigner SH, Marker J, Burger PC, et al. Specific chromosomal abnormalities in malignant human gliomas. Cancer Res 1998;48:405-11.
23. Rasheed BKA, Stenzel TT, McLendon RE, et al. PTEN gene mutations are seen in high grade, but not in low-grade gliomas. Cancer Res 1996;57:4187-96.
24. Davies MP, Gibss FE, Halliwell N, et al. Mutation in the PTEN/MMAC1 gene in archival low grade and high grade gliomas. Br J Cancer 1999;79:1542-8.
25. Hill JR, Kuriyama N, Kuriyama H, et al. Molecular genetics of brain tumor. Arch Neurol 1999;56:439-42.
26. Maier D, Zhang Z, Taylor E, et al. Somatic deletion mapping on chromosome 10 and sequence analysis of PTEN/MMAC1 point to the 10q25-26 region as the primary target in low grade and high-grade gliomas. Oncogens 1998;16:3331-5.
27. Wang SI, Puc J, Li J, et al. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 1997;57:4183-6.
28. Knobbe CB, Merlo A, Reinfenberger G. PTEN signaling in gliomas. Neuro-oncol 2002;4:196-211.